News | November 01, 2021
GlaxoSmithKline posts Q2FY22 consolidated PAT at Rs. 204.24 Cr
GlaxoSmithKline Pharmaceuticals Limited has reported consolidated financial results for the period ended September 30, 2021
GlaxoSmithKline Pharmaceuticals Limited has reported consolidated financial results for the period ended September 30, 2021
The company is a medical dictation solution used by medical practitioners
It provides an option to automatically perform nodule detection immediately after chest X-ray imaging
_256_384.jpg)
Both parties are expected to invest a total of US $ 1 million to establish the brand
The release of this batch will secure the supply for hospitals and cancer centres that are involved in the clinical trials managed by the company
Its unique technology, ChetoSensar gives new promise to ADCs by alleviating solubility challenges
The acquisition expands Takeda’s immuno-oncology and innate immune cell therapy portfolio with novel platforms leveraging T cells for the potential treatment of solid tumours and haematological malignancies
The collaboration provides KardiaMobile users quick access to doctors worldwide for consultations about their ECG readings
Two leaders in science combine complementary best-in-class technologies for biologics manufacturing customers
Gini Health works in the domain of personalised healthcare
Subscribe To Our Newsletter & Stay Updated
